PTC THERAPEUTICS, INC. (NASDAQ:PTCT) Files An 8-K Results of Operations and Financial Condition

PTC THERAPEUTICS, INC. (NASDAQ:PTCT) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Story continues below

On January 7, 2019, PTC Therapeutics, Inc. (the “Company”) issued a press release (the “press release”) announcing certain preliminary (unaudited) financial information for its fiscal year ending December 31, 2018, including that the Company expects to report (i) TranslarnaTM(ataluren) net product revenue for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) of approximately $171 million; (ii) EMFLAZA™ (deflazacort) net product revenue for the treatment of Duchenne muscular dystrophy (DMD) of approximately $91million; and (iii) ending cash and cash equivalents of approximately $227 million. Final results are subject to completion of the Company’s year-end audit.

Item 7.01.Regulation FD Disclosure.

The Company also announced financial guidance for its fiscal year ending December 31, 2019 in the press release, including that the Company anticipates (i) full-yearnet productrevenuesto be between $285 and $305 million and (ii) GAAPR&D and SG&Aexpense for the full year 2019 to be between $395 and $405million with non-GAAPR&D and SG&Aexpensefor the full year 2019 to be between $360 and $370million, excluding estimated non-cash, stock-based compensation expense of approximately $35 million.

The Company announced that on Tuesday, January 8th at 5:00 pm PT at the 37th Annual J.P. Morgan Healthcare Conference (the “Conference”), the Company will present its 2019 strategic priorities, preliminary 2018 financial results, and 2019 financial guidance. The presentation will be webcast live and the accompanying slide deck has been posted on the Events and Presentations page under the Investors section of the Company’s website. A copy of the slide deck, which the Company intends to utilize in various meetings at the Conference, is also attached as Exhibit 99.2.

This Current Report on Form 8-K and Exhibits 99.1 and 99.2 include a forward-looking financial measure that was not prepared in accordance with accounting principles generally accepted in the United States (GAAP), non-GAAP R&D and SGA expenses (which excludes non-cash stock-based compensation expense). Management uses this measure when assessing and identifying operational trends and, in management’s opinion, this non-GAAP measure is useful to investors and other users of its financial statements by providing greater transparency into the historical and projected operating performance of PTC and the Company’s future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP.

The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward Looking Statements:All statements, other than those of historical fact, contained in this Current Report on Form 8-K, are forward-looking statements, including preliminary (unaudited) financial information for fiscal year 2018 and financial guidance for fiscal year 2019. The Company’s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to the preliminary nature of the Company’s 2018 financial information, which is subject to completion of the Company’s year-end audit; the assumptions underlying the Company’s financial guidance for 2019; and the factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, Quarterly Reports on Form 10-Q for the periods ended March 31, 2018, June 30, 2018 and September 30, 2018 and Exhibit 99.2 to PTC’s Current Report on Form 8-K filed on August 24, 2018 as well as any updates to these risk factors filed from time to time in the Company’s other filings with theSEC. You are urged to carefully consider all such factors. The forward-looking statements contained herein and the exhibits hereto represent the Company’s views only as of the date of this Current Report on Form 8-K and the Company does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this Current Report on Form 8-K except as required by law. All website addresses given in this Current Report on Form 8-K or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

EX-99.1 2 ex9912019-01x07ptcjpmnewsr.htm EXHIBIT 99.1 Exhibit PTC Therapeutics Provides Corporate Update and Outlines 5-year Strategic Plan at 2019 J.P. Morgan Healthcare Conference- Multiple products to be launched by 2023 potentially generating ~$1.5 billion revenue annually- – Plan to submit BLA in 2H 2019 for AADC gene therapy program — Risdiplam regulatory filing targeted for 2H 2019 – – TEGSEDI™ filed in Brazil for expected approval in 2019 — Duchenne franchise continuing to expand – SOUTH PLAINFIELD,…
To view the full exhibit click here


PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) in collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596). It has two compounds in clinical development within the SMA program: RG7800 and RG7916.

An ad to help with our costs